Trials / Unknown
UnknownNCT05495685
iDentification and vAlidation Model of Liquid biopsY Based cfDNA Methylation and pRotEin biomArKers for Pancreatic Cancer (DAYBREAK Study)
Pancreatic Cancer Detection by Liquid Biopsy in Peripheral Blood: A Prospective Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 450 (estimated)
- Sponsor
- Changhai Hospital · Academic / Other
- Sex
- All
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
DAYBREAK is a prospective, multi-omics, observational study aimed at early detecting pancreatic cancer by combined assays for biomarkers of cfDNA methylation, serum protein markers, blood miRNA markers and others, in which of 450 participants will be enrolled. The development and validation of the model will be conducted in participants with early stage cancers and benign disease through a two-stage approach. The sensitivity and specificity of the model in pancreatic cancer early detection will be evaluated.
Conditions
Timeline
- Start date
- 2022-03-24
- Primary completion
- 2023-12-31
- Completion
- 2024-06-30
- First posted
- 2022-08-10
- Last updated
- 2022-08-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05495685. Inclusion in this directory is not an endorsement.